Prostvac-V/F, an investigational prostate cancer vaccine regimen, does not improve overall survival among men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer, according to the findings of the phase 3 PROSPECT trial. Read the article here.
Prostate Cancer Vaccine Found Not To Improve Survival Read More »
March 2018 Awareness Night How clinical trials have changed prostate cancer care Dr. Andrew Loblaw BSc MD MSc FRCPC CIP Clinician Scientist , Ontario Association of Radiation OncologyStaff Radiation Oncologist & Clinician Scientist, Sunnybrook Health Sciences Centre Scientist, Sunnybrook Research Institute Fellow, American Society of Clinical Oncology (ASCO) Co-Chair, GU group for Cancer Care Ontario’s Program in Evidence-Based Care Previous Co-Chair, ASCO’s Genitourinary Advisory Group Professor, Department of Radiation Oncology at University of Toronto Professor,The Institute of Health Policy, Management and Evaluation (IHPME) CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 66:27 minutes
Video: “How clinical trials have changed prostate cancer care” Read More »
The survival rate for early-stage prostate cancer is 99 percent after 10 years, regardless of whether men undergo surgery, radiation or are “actively monitored,” according to studies published Wednesday. Researchers hailed the results as good news, saying they had been expecting a survival rate of 90 percent. This article is hopeful, but leaves questions. It’s not clear how ‘early is defined or whether the arms were truly randomized. Read the article, carefully.
Almost all men with early prostate cancer survive 10 years, regardless of treatment Read More »
A clinical trial at Sunnybrook Hospital in Toronto will determine the effectiveness of a targeted radiotherapy approach, stereotactic body radiotherapy (SBRT), in improving outcomes for men with oligometastatic prostate cancer. Read the article.
Advances in targeted radiation for prostate cancer Read More »
The Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. The primary objective is to determine whether MRI imaging can spare some men from undergoing a biopsy and avoid the possible associated side effects. The trial will be led by Dr. Laurence Klotz of the Sunnybrook Research Institute in Toronto. Read the article.
Clinical trial will test use of MRI to improve prostate cancer diagnosis and management Read More »
Several key questions that a participant will want answered before enrolling in a clinical trial are listed here. It is important that people learn as much as possible prior to entering a trial, and to thoroughly discuss the study with a doctor and with the study team. Read the article.
Questions to Ask Before Participating in a Prostate Cancer Clinical Trial Read More »
A study that you probably won’t be reading in your daily paper or favourite news website anytime soon casts serious doubts on the reliability of mainstream medical and health journalism. The study found that 51% of news items reporting on medical trials – specifically on randomised controlled trials (RCTs), which are seen as the gold standard in judging whether a treatment is effective or safe – were subject to “spin”. Read the article.
Half of medical reporting ‘is subject to spin’ Read More »